These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 8740931

  • 1. New therapeutic agents for the treatment of NIDDM.
    Kuehnle HF.
    Exp Clin Endocrinol Diabetes; 1996; 104(2):93-101. PubMed ID: 8740931
    [Abstract] [Full Text] [Related]

  • 2. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E, Minuto F, Colao A, Ferone D.
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [Abstract] [Full Text] [Related]

  • 3. [The thiazolidinones--a new therapeutic agent for type 2 diabetes].
    Bethge H, Häring HU.
    Arzneimittelforschung; 1998 Feb; 48(2):97-119. PubMed ID: 9541719
    [Abstract] [Full Text] [Related]

  • 4. Type II diabetes and syndrome X. Pathogenesis and glycemic management.
    Karam JH.
    Endocrinol Metab Clin North Am; 1992 Jun; 21(2):329-50. PubMed ID: 1612069
    [Abstract] [Full Text] [Related]

  • 5. Effects of troglitazone on insulin sensitivity.
    Henry RR.
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S148-50. PubMed ID: 8894499
    [Abstract] [Full Text] [Related]

  • 6. Promising new approaches.
    Reasner CA.
    Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
    [Abstract] [Full Text] [Related]

  • 7. [Insulin resistance and cardiovascular complications].
    Janka HU.
    Wien Klin Wochenschr; 1994 May; 106(24):758-62. PubMed ID: 7846894
    [Abstract] [Full Text] [Related]

  • 8. [Does targeted therapy of type 2 diabetes prevent cardiovascular incidents?].
    Leschke M.
    Med Klin (Munich); 2003 Oct 15; 98 Suppl 1():12-6. PubMed ID: 14694836
    [Abstract] [Full Text] [Related]

  • 9. Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium.
    Nathanson D, Nyström T.
    Mol Cell Endocrinol; 2009 Jan 15; 297(1-2):112-26. PubMed ID: 19038307
    [Abstract] [Full Text] [Related]

  • 10. The role of troglitazone in treating the insulin resistance syndrome.
    Granberry MC, Schneider EF, Fonseca VA.
    Pharmacotherapy; 1998 Jan 15; 18(5):973-87. PubMed ID: 9758309
    [Abstract] [Full Text] [Related]

  • 11. [Amylin as an additional possible pathogenic factor in NIDDM and the insulin resistance syndrome].
    Hrnciar J.
    Vnitr Lek; 1996 Aug 15; 42(8):557-60. PubMed ID: 8967027
    [Abstract] [Full Text] [Related]

  • 12. Hyperinsulinemia and atherosclerosis.
    Standl E.
    Clin Invest Med; 1995 Aug 15; 18(4):261-6. PubMed ID: 8549011
    [Abstract] [Full Text] [Related]

  • 13. On the pathophysiology of late onset non-insulin dependent diabetes mellitus. Current controversies and new insights.
    Vaag A.
    Dan Med Bull; 1999 Jun 15; 46(3):197-234. PubMed ID: 10421979
    [Abstract] [Full Text] [Related]

  • 14. Plasma cell membrane glycoprotein 1 (PC-1): a marker of insulin resistance in obesity, uremia and diabetes mellitus.
    Stefanović V, Antić S.
    Clin Lab; 2004 Jun 15; 50(5-6):271-8. PubMed ID: 15209435
    [Abstract] [Full Text] [Related]

  • 15. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
    Sironi AM, Vichi S, Gastaldelli A, Pecori N, Anichini R, Foot E, Seghieri G, Ferrannini E.
    Clin Pharmacol Ther; 1997 Aug 15; 62(2):194-202. PubMed ID: 9284856
    [Abstract] [Full Text] [Related]

  • 16. Long-term cardiovascular effects of insulin sensitizer troglitazone on non-diabetic individuals with insulin resistance: double blind, prospective randomized study.
    Stakos DA, Schuster DP, Sparks EA, Wooley CF, Osei K, Boudoulas H.
    J Cardiol; 2003 Apr 15; 41(4):183-90. PubMed ID: 12728539
    [Abstract] [Full Text] [Related]

  • 17. Insulin resistance, diabetes and cardiovascular risk: approaches to treatment.
    Rosenberg DE, Jabbour SA, Goldstein BJ.
    Diabetes Obes Metab; 2005 Nov 15; 7(6):642-53. PubMed ID: 16219008
    [Abstract] [Full Text] [Related]

  • 18. Therapy for type 2 diabetes mellitus.
    Elson DF, Meredith M.
    WMJ; 1998 Mar 15; 97(3):49-54. PubMed ID: 9540451
    [Abstract] [Full Text] [Related]

  • 19. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study.
    Savage S, Estacio RO, Jeffers B, Schrier RW.
    Proc Assoc Am Physicians; 1997 Mar 15; 109(2):181-9. PubMed ID: 9069587
    [Abstract] [Full Text] [Related]

  • 20. New drugs and clinical trials in diabetes and hypertension.
    Nilsson P.
    Exp Clin Endocrinol Diabetes; 1997 Mar 15; 105 Suppl 2():64-9. PubMed ID: 9288549
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.